6838 — Formosa Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- TWD3.82bn
- TWD2.63bn
- TWD9.50m
Brief: Harrow Acquires U.S. Commercial Rights To Byqlovi™ From Formosa Pharmaceuticals
US FDA approves Eyenovia's eye drug, Formosa Pharma says (updated)
US FDA approves Eyenovia's eye drug, Formosa Pharma says
Brief: Formosa Pharmaceuticals And Aimmax Therapeutics Receive FDA Approval For Clobetasol Propionate Ophthalmic Suspension 0.05%
Eyenovia rises as William Blair initiates coverage with 'outperform' rating
Eyenovia rises on deal with Taiwan-based Formosa Pharma for eye treatment
Brief: Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals
Brief: Formosa Pharmaceuticals Announces Development Collaboration Agreement With Eyenovia